Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

eUpdate – Cancer of the Prostate Treatment Recommendations

eUpdate – Cancer of the Prostate Treatment Recommendations

Published: 28 September 2017. Authors: ESMO Guidelines Committee

Note: Other eUpdates may have been published for these guidelines. All currently valid eUpdates can be accessed from the page displaying the full guidelines on this topic

Clinical Practice Guidelines

This update refers to the Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Parker C., Gillessen S., Heidenreich A. et al. Ann Oncol 2015; 26 (Suppl 5): v69-v77.

Section

Management of advanced/metastatic disease

Text update

Two phase III trials have compared ADT alone versus ADT plus abiraterone and prednisolone in men with metastatic, hormone-naive disease.  The LATITUDE trial included men with high risk metastatic disease.  Based on 406 events, abiraterone/prednisone improved overall survival (HR: 0.62, 95% CI: 0.51-0.76) [1].  The STAMPEDE trial included men with metastatic and non-metastatic disease.  Based on 446 events, abiraterone/prednisone improved overall survival (HR: 0.63, 95% CI: 0.52-0.76) [2].

Recommendations

  • ADT plus abiraterone/prednisone may be considered as first-line treatment for metastatic, hormone-naive disease [I, A].

References

  1. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Fizazi et al. N Engl J Med. 2017 Jul 27;377(4):352-360
  2. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. James et al. N Engl J Med. 2017 Jul 27;377(4):338-351

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings